Envafolimab plus axitinib for first-line advanced kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of an immunotherapy (Envafolimab) with a targeted therapy pill (Axitinib) as the first treatment for advanced kidney cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your kidney cancer must be clear cell type and cannot be removed by surgery or has spread to other parts of the body.
- You cannot have had any prior cancer treatment for this kidney cancer.
- You must be in fairly good health, able to take care of yourself (ECOG 0 or 1).
- Your blood counts, liver, and kidney function must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two medications (Envafolimab and Lenvatinib) for people with a type of kidney cancer called clear cell renal cell carcinoma that has spread to the liver. The goal is to see if this combination can shrink or control the liver tumors.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This Phase 2 trial studies whether combining axitinib and pembrolizumab can shrink and control metastatic or inoperable type 2 or mixed papillary kidney cancer. It may help by blocking cancer growth signals and boosting the immune system to attack the cancer.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Advanced Renal Cell Carcinoma (aRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.